"Carboplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An organoplatinum compound that possesses antineoplastic activity.
Concept/Terms
Carboplatin- Carboplatin
- cis-Diammine(cyclobutanedicarboxylato)platinum II
- CBDCA
Ribocarbo- Ribocarbo
- ribosepharm Brand of Carboplatin
Nealorin- Nealorin
- Prasfarma Brand of Carboplatin
Neocarbo- Neocarbo
- Neocorp Brand of Carboplatin
Paraplatin- Paraplatin
- Carboplat
- Paraplatine
- Bristol-Myers Squibb Brand of Carboplatin
Carbosin- Carbosin
- Pharmachemie Brand of Carboplatin
Carbotec- Carbotec
- Columbia Brand of Carboplatin
Ercar- Ercar
- Almirall Brand of Carboplatin
Platinwas- Platinwas
- Chiesi Brand of Carboplatin
Below are MeSH descriptors whose meaning is more general than "Carboplatin".
Below are MeSH descriptors whose meaning is more specific than "Carboplatin".
This graph shows the total number of publications written about "Carboplatin" by people in Harvard Catalyst Profiles by year, and whether "Carboplatin" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 6 | 7 |
1995 | 2 | 6 | 8 |
1996 | 1 | 5 | 6 |
1997 | 1 | 6 | 7 |
1998 | 2 | 5 | 7 |
1999 | 3 | 4 | 7 |
2000 | 0 | 5 | 5 |
2001 | 3 | 8 | 11 |
2002 | 2 | 4 | 6 |
2003 | 0 | 11 | 11 |
2004 | 2 | 4 | 6 |
2005 | 4 | 17 | 21 |
2006 | 6 | 17 | 23 |
2007 | 4 | 3 | 7 |
2008 | 4 | 18 | 22 |
2009 | 4 | 12 | 16 |
2010 | 5 | 16 | 21 |
2011 | 4 | 20 | 24 |
2012 | 4 | 17 | 21 |
2013 | 2 | 13 | 15 |
2014 | 2 | 17 | 19 |
2015 | 8 | 14 | 22 |
2016 | 7 | 18 | 25 |
2017 | 5 | 8 | 13 |
2018 | 3 | 15 | 18 |
2019 | 5 | 16 | 21 |
2020 | 3 | 11 | 14 |
2021 | 2 | 15 | 17 |
2022 | 1 | 13 | 14 |
2023 | 0 | 9 | 9 |
2024 | 0 | 2 | 2 |
Below are the most recent publications written about "Carboplatin" by people in Profiles.
-
Tracing back primed resistance in cancer via sister cells. Nat Commun. 2024 Feb 07; 15(1):1158.
-
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3ß Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies. Clin Cancer Res. 2024 Feb 01; 30(3):522-531.
-
Improved survival for stage IV sinonasal small cell neuroendocrine carcinoma treated with chemotherapy and anti-PD-L1 therapy. BMJ Case Rep. 2023 Nov 17; 16(11).
-
Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization. Allergy. 2024 Mar; 79(3):679-689.
-
H-Dot Mediated Nanotherapeutics Mitigate Systemic Toxicity of Platinum-Based Anticancer Drugs. Int J Mol Sci. 2023 Oct 23; 24(20).
-
Flashback Foreword: Carboplatin Dosage Based on Renal Function. J Clin Oncol. 2023 10 01; 41(28):4451-4452.
-
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. JCO Precis Oncol. 2023 Sep; 7:e2300235.
-
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial. Int J Cancer. 2024 01 01; 154(1):114-123.
-
Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors. J Natl Cancer Inst. 2023 07 06; 115(7):831-837.
-
Tolerability of ifosfamide-containing regimen in patients with high-risk renal and INI-1-deficient tumors. Pediatr Blood Cancer. 2023 Aug; 70(8):e30422.